Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > docetaxel (Taxotere)

Taxotere (docetaxel) : Aventis : Chemotherapeutic agent

Docetaxel (Taxotere) Clinical Research
Docetaxel (Taxotere) Side Effects
Docetaxel (Taxotere) & Gemcitabine (Gemzar)
Docetaxel (Taxotere) & Vinorelbine (Navelbine)
Docetaxel (Taxotere) & Platinum (Cisplatin or Carboplatin)

Clinical Research

Neoadjuvant Docetaxel (Taxotere) Improves Life Expectancy in Locally Advanced Lung Cancer (Doctor's Guide)
Reports research presented at the 9th World Congress on Lung Cancer (September 2000) that showed docetaxel (Taxotere) used as neoadjuvant therapy improves survival over local treatment alone in patients with locally advanced NSCLC. [9/00]

Taxotere Monotherapy Increases Survival in Lung Cancer Patients (Doctor's Guide)
Summarizes research presented at the 10th meeting of the European Congress of Clinical Oncology (ECCO) that showed monotherapy with Taxotere (docetaxel) to be an effective first-line chemotherapy treatment for patients with advanced non-small cell lung cancer. [9/99]

Taxotere (Docetaxel) - Recent MEDLINE Abstracts (PubMed)

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients with NSCLC Previously Treated with Platinum-based Chemotherapy (Journal of Clinical Oncology)
Abstract of a Journal of Clinical Oncology article (May 2000) reporting results of a study that found treatment with docetaxel is associated with significant prolongation of survival when compared to best supportive care in patients with NSCLC who had previously been treated with platinum-based chemotherapy. [5/00]

Consolidation Docetaxel After Chemoradiotherapy Encouraging in NSCLC (Doctor's Guide)
Reports on a study published in the May 15, 2003 issue of the Journal of Clinical Oncology that found the use of docetaxel (Taxotere) after cisplatin/etoposide plus radiotherapy produces high survival rates in patients with Stage IIIB NSCLC. [5/03]

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide In Patients with Advanced NSCLC Previously Treated with Platinum Containing Chemotherapy Regimens (Journal of Clinical Oncology)
Abstract of a study published in the June 2000 issue of the Journal of Clinical Oncology that found, in a randomized trial, that docetaxel (75 mg/m2) every 3 weeks can offer clinically meaningful benefit to patients with advanced NSCLC whose disease has relapsed or progressed after platinum-based chemotherapy.
[6/00]

Taxotere (Docetaxel) - Clinical Trials (ClinicalTrials.gov)



Side Effects

 



Docetaxel (Taxotere) & Gemcitabine (Gemzar)

Taxotere (Docetaxel) Plus Gemzar (Gemcitabine) Doubles Anti-Tumor Effect in Relapsed Lung Cancer (Doctor's Guide)
Reports that the combination of weekly Gemzar (Gemcitabine) and monthly Taxotere (Docetaxel) is active and safe in patients with advanced NSCLC who have failed prior chemotherapy according to the results of a Phase II trial presented at ASCO 2000. Notes that durable responses were observed at all disease sites and in cancers refractory to prior platinum therapy. [5/00]



Docetaxel (Taxotere) and Vinorelbine (Navelbine)

Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Non-Small Cell Lung Cancer (Journal of Clinical Oncology)
Abstract of a Journal of Clinical Oncology article (March 2000) reporting the results of a study that found docetaxel and vinorelbine, both given every two weeks, is a highly active combination for the treatment of advanced NSCLC. [3/00]



Docetaxel (Taxotere) and Platinum (Cisplatin or Carboplatin)

 



 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 26-Apr-2011
Karen Parles, MLS Editor